These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 17355491)
1. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Sulak P; Willis S; Kuehl T; Coffee A; Clark J Headache; 2007 Jan; 47(1):27-37. PubMed ID: 17355491 [TBL] [Abstract][Full Text] [Related]
2. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Coffee AL; Kuehl TJ; Willis S; Sulak PJ Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986 [TBL] [Abstract][Full Text] [Related]
3. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Coffee AL; Sulak PJ; Kuehl TJ Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150 [TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
5. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives. Coffee AL; Kuehl TJ; Sulak PJ Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656 [TBL] [Abstract][Full Text] [Related]
6. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Sulak PJ; Kuehl TJ; Coffee A; Willis S Am J Obstet Gynecol; 2006 Oct; 195(4):935-41. PubMed ID: 16647684 [TBL] [Abstract][Full Text] [Related]
7. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. Kaunitz AM; Portman DJ; Hait H; Reape KZ Contraception; 2009 May; 79(5):350-5. PubMed ID: 19341846 [TBL] [Abstract][Full Text] [Related]
8. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen. Kuehl TJ; Speikermann AM; Willis SA; Coffee A; Sulak PJ J Reprod Med; 2008 Apr; 53(4):266-70. PubMed ID: 18472649 [TBL] [Abstract][Full Text] [Related]
9. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). Barbosa IC; Filho CI; Faggion D; Baracat EC Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291 [TBL] [Abstract][Full Text] [Related]
10. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone. Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819 [TBL] [Abstract][Full Text] [Related]
11. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962 [TBL] [Abstract][Full Text] [Related]
12. A look at the long-term safety of an extended-regimen OC. Davis MG; Reape KZ; Hait H J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148 [TBL] [Abstract][Full Text] [Related]
14. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Davis AR; Westhoff C; O'Connell K; Gallagher N Obstet Gynecol; 2005 Jul; 106(1):97-104. PubMed ID: 15994623 [TBL] [Abstract][Full Text] [Related]
15. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use. Sänger N; Stahlberg S; Manthey T; Mittmann K; Mellinger U; Lange E; Kuhl H; Wiegratz I Contraception; 2008 Jun; 77(6):420-5. PubMed ID: 18477491 [TBL] [Abstract][Full Text] [Related]
16. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines. Coffee AL; Sulak PJ; Hill AJ; Hansen DJ; Kuehl TJ; Clark JW J Womens Health (Larchmt); 2014 Apr; 23(4):310-7. PubMed ID: 24450487 [TBL] [Abstract][Full Text] [Related]
17. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Foidart JM; Sulak PJ; Schellschmidt I; Zimmermann D; Contraception; 2006 Jan; 73(1):34-40. PubMed ID: 16371292 [TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM; Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578 [TBL] [Abstract][Full Text] [Related]
20. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D; Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]